Targeting CXCR4/CXCL12 axis via [ < sup > 177 < /sup > Lu]Lu-DOTAGA.(SA.FAPi) < sub > 2 < /sub > with CXCR4 antagonist in triple-negative breast cancer

CONCLUSION: The combination of [177Lu]Lu-DOTAGA.(SA.FAPi)2 and AMD3100 is a feasible treatment against TNBC with minimal toxicity in main organs.PMID:38587644 | DOI:10.1007/s00259-024-06704-y

Source: Molecular Medicine - April 8, 2024 Category: Molecular Biology Authors: Guangfa Bao Ziqiang Wang Luoxia Liu Buchuan Zhang Shuang Song Dongdong Wang Siyuan Cheng Eu-Song Moon Frank Roesch Jun Zhao Bo Yu Xiaohua Zhu Source Type: research